BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Pharm Country

  Tyme Provides Update on At-The-Market Financing Activity

  Between November 6 and December 4, 2017, the Company sold approximately 1.2 million shares of Tyme common stock at an average price of $4.05 per share.

  December 5, 2017

   · 

  4 min read
• Drug Development

  Actinium Pharmaceuticals Unveils Actimab-MDS and Planned Phase II Trial in Myelodysplastic Syndromes Targeted at Patients With High-Risk p53+ Genetic Mutations

  Actinium, together with Dr. Roboz, will conduct a webcast at 8 AM ET on December 5, 2017 to introduce Actimab-MDS and the planned Phase 2 trial.

  December 5, 2017

   · 

  8 min read
• FDA

  Sonoma Pharmaceuticals Announces Second FDA Approval to Add Antimicrobial Language to Alevicyn Gel Products for Management of Atopic Dermatitis

  Second FDA approval in as many months further validates expanding adoption of Alevicyn products by dermatologists.

  December 5, 2017

   · 

  4 min read
• 

  Business

  Hologenix Appoints Jim Calhoun CEO

  He replaces co-founder, Seth Casden in the CEO position, enabling Casden to focus on sales, science and innovation.

  December 5, 2017

   · 

  2 min read
• Business

  AMPEL BioSolutions, Horizon Pharma, and Lupus Research Alliance Partner on Unique Clinical Trial for Patients With Lupus

  The RIFLE trial will utilize Horizon Pharma’s proprietary prednisone delayed-release tablets, RAYOS, to address the daily cycling of cortisol and inflammatory mediators known as circadian rhythm.

  December 5, 2017

   · 

  4 min read
• 

  Business

  Purigen Biosystems Appoints Life Science Industry Veteran Barney Saunders, PhD, as CEO

  Dr. Saunders brings 30 years of experience managing emergent technologies and commercializing disruptive products for life science tools and diagnostics companies.

  December 5, 2017

   · 

  2 min read
• Drug Development

  Immunovaccine Announces Positive Clinical Data from Its Collaborative Combination Immunotherapy Trial in Advanced Ovarian Cancer

  Initial results from ten evaluable patients in the DPX-Survivac plus 100 mg epacadostat dosing cohort demonstrate a disease control rate of 70%.

  December 5, 2017

   · 

  7 min read
• Drug Development

  ObsEva Initiates PROLONG, the Phase IIa Clinical Trial of OBE022 in Preterm Labor

  The PROLONG trial is the first clinical trial of OBE022 in pregnant women presenting with spontaneous preterm labor at gestational ages between 24 and 34 weeks.

  December 5, 2017

   · 

  7 min read
• 

  BioForest

  Neuropace’s Brain Implant Reduces Epilepsy Seizures in 8-Year Trial

  Key findings from these prospective trials demonstrate sustained, long-term patient benefits.

  December 5, 2017

   · 

  4 min read
• Business

  Sunesis’ CEO Resigns, Effective Dec. 31, 2017

  Mr. Swisher will remain with the Company as a Strategic Advisor to the Board of Directors through 2018.

  December 5, 2017

   · 

  4 min read